NEW DELHI: The government has recently granted consent to four waitlisted companies under the manufacturing related incentive (PLI) scheme for national production of bulk drugs,” an official announcement said on Monday.
The section of pharmaceuticals had established the PLI strategy for marketing of domestic production of critical bulk medications — Crucial Beginning Materials (KSMs)/ Drug Intermediates and Active Pharmaceutical Ingredients (APIs).
It envisages setting up greenfield plants at four distinct target sections with a complete cost of Rs 6,940 crore for the interval 2020-21 into 2029-30.
Each of the 215 applications acquired for its 36 products spread over the four target segments were assessed and considered and selected participants informedthe ministry of fertilizers and chemicals stated.
Presently, four waitlisted applicants that are otherwise qualified have been accepted contrary to slots vacated by withdrawal from firms which had previously been granted blessings, ” the ministry stated.
The firms That Have been given consent are — Solara Lively Pharma Science Ltd, Rajasthan Antibiotics Ltd, Dhatri Lab Pvt Ltd and Vital Laboratories Pvt Ltd.
.
The goods that approval was given are 1,1 Cyclohexane Diacetic Acid, Meropenem, Ritonavir and Levofloxacin, ” the announcement said.
“For this, a total of 46 programs with dedicated investment of Rs 5,355.
44 crore and anticipated job generation of roughly 11,210 are accepted by the authorities up to now beneath the PLI Scheme for Bulk Drugs,” the ministry stated.
Setting up of those plants will produce the nation tolerable to some huge extent in regard of those mass drugs, ” it included.
4 Companies get Acceptance under PLI Strategy for bulk drugs
